AIHealthcare Analytics

Knowledge Wiki

Wiki › FDA, CMS Scramble to Avoid Regulatory Logjam as More States Look to Test AI in Clinical Settings

FDA, CMS Scramble to Avoid Regulatory Logjam as More States Look to Test AI in Clinical Settings

OVERVIEW
Rev 3 Oct 31, 2026 05:42 UTC 2 sources

Federal regulators (FDA and CMS) are coordinating behind-the-scenes efforts to prevent regulatory conflicts as states increasingly launch AI clinical testing sandboxes. The coordination addresses jurisdictional ambiguity between federal device oversight and state medical practice authority. Regulatory Tension: States like Utah are approving autonomous AI systems (prescription refills, drug management) that may fall under FDA's medical device purview. Simultaneous federal and state oversight creates compliance uncertainty for health systems and vendors. FDA and CMS officials are reportedly working to clarify regulatory pathways and avoid duplicative or contradictory requirements. Path Forward: Federal-state coordination frameworks are emerging to streamline AI device authorization. The FDA's TEMPO pilot and discussions with states suggest a potential division: FDA handles pre-market safety/efficacy validation; states oversee clinical implementation and practice scope. Clarity on this division remains incomplete, creating ongoing uncertainty for AI vendors and health systems. ---

Sources: harvested
🔒

Subscribe to read full wiki analysis

Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.

View Plans & Subscribe

New users get a 7-day trial — no credit card required.

← Back to Wiki Index